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Abstract
Background: Serous cystadenomas of pancreas are rare benign epithelial neoplasms, which predominantly occur in the
pancreatic body and tail of elderly females. Majority of these tumors have microcystic appearance. Macrocystic and solid
variants have also been described. A number of more aggressive cystic pancreatic lesions are included in the differential
diagnosis. Distinction from such lesions is important for optimal management.
Objective: Our aim was to study the clinical and histological features of serous cystadenomas which would be helpful
in making their correct diagnosis and understanding their behavior.
Methods: We reviewed 23 cases of serous cystadenomas diagnosed in our institution between January 2001 and June 2018.
Results: Mean age at presentation was 53.43 years. Female to male ratio was 4.75:1. Over half (56.5%) of the cases were
diagnosed incidentally. Abdominal pain was the most common symptom. Body and tail (either alone or in combination)
were the most common locations. Tumor size ranged from 2 to 16 cm. Central scar was seen in 43.4% cases. Two cases
were unilocular (macrocystic). Microscopically, all cases showed simple cuboidal to flattened epithelium with round,
uniform nuclei, and glycogen-rich clear cytoplasm. Focal micropapillae formation was seen in eight cases (34.7%). Surgical
resection was performed in 82.6% cases. Recurrence occurred in only one single case.
Conclusion: Pancreatic serous cystadenomas are benign neoplasms with excellent prognosis. The tumors showed
typical morphological features in all cases. Surgical resection was performed in the majority of cases in our study owing
to lack of optimal and complete radiological workup pre-operatively and the concern for not missing and adequately
treating pancreatic mucinous cystic neoplasms.
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Introduction

1Section

Serous cystadenomas (SCs) are rare but distinct benign neoplasms of pancreas. According to various published articles,
they comprise 1%–2% of all pancreatic neoplasms and
10%–29% of pancreatic cystic neoplasms.1–3 SCs are more
common in the elderly and show a female predominance.4
Abdominal pain and palpable abdominal mass are the most
common presenting complaints, but a significant proportion
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is asymptomatic and is diagnosed as an incidental finding.5,6
SCs are associated with von Hippel–Lindau (VHL) disease
and with many sporadic tumors.4,7,8 Majority of these lesions
involve the body and/or tail of pancreas.3,9 Radiologically,
typical cases have a polycystic (honeycomb) appearance
with a central stellate scar seen in few cases.10
Grossly, majority of SCs are well circumscribed, and the
cut surface exhibits numerous small cystic spaces filled
with clear serous fluid (microcystic SCs). These cystic
spaces are separated by thin fibrous septae, which coalesce
to form the fibrous stellate scar. Of the other variants, the
macrocystic/oligocystic variant is poorly demarcated and
has fewer but larger cystic spaces. The solid variant appears
as a well-circumscribed solid nodule lacking any grossly
visible cystic spaces.1,4,11–13 All these macroscopic variants
are histologically composed of characteristic flattened to
cuboidal, glycogen-containing epithelial cells with round
uniform nuclei. Intervening stroma shows a network of
small vascular channels.1,3,4
SCs run a benign, indolent clinical course and have an
excellent prognosis. They are slow growing, malignant progression is rare, and disease mortality is almost nil. Surgical
excision is curative but is required only in minority of cases
when tumors are large or causing significant (or related)
symptoms or when preoperative diagnosis was uncertain in
spite of extensive workup including computed tomography
(CT) scan, magnetic resonance imaging (MRI), and endoscopic ultrasonography. It is also required in the exceptional cases where concern of malignancy exists. Large
majority of these tumors may require conservative management only.14–16 Recurrence is seen rarely in locally aggressive tumors.5
The aim of our study was to describe the clinical and
histopathological features of SCs of pancreas which would
be helpful in making their correct diagnosis and understanding their behavior.

Materials and methods
We retrieved 23 cases of SC of pancreas from the surgical
pathology database of the Section of Histopathology, Aga
Khan University Hospital reported between January 2001
and June 2018 through “Integrated Laboratory Management
System (ILMS)” software. Clinical information regarding
age, sex, exact location in pancreas, presenting complaints,
tumor size, and gross appearance was obtained from the
surgical pathology reports. Hematoxylin and Eosin (H&E)stained microscopic glass slides were reviewed by two
authors (M.U.T. and N.U.D.) to assess histological features
such as micropapillary architecture, epithelial cell morphology, and calcification and extension into peripancreatic
adipose tissue. Follow-up information for nine patients
treated at our institution was available from the patients’
records which were reviewed. These records contained
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findings of CT scans performed on each follow-up visit.
Follow-up information for patients treated at other institutions was obtained from the patients verbally via telephonic
conversation.

Results
Ages of patients at the time of presentation ranged from 23
to 79 years with mean and standard deviation (SD) of
53.43 years ± 14.88 and 50 years. Of the 23 patients, 19
(82.6%) were females and 4 (17.4%) were males. The F:M
ratio was median of 4.7:1. Symptoms related to pancreatic
lesions were seen in 10 cases (43.5%) with abdominal pain
being the most common (5 cases or 21.7%), followed by
jaundice (3 or 13%). None of the 19 female patients in the
study had any history of alcohol consumption and/or smoking. Clinical information regarding body mass index (BMI)
was not available in any of the cases. Preoperative serum
carcinoembryonic antigen (CEA) levels were available in
two cases and were within normal limits. Serum CA 19-9
levels were available in three patients and were found to be
elevated in two cases. In five cases (21.7%), the tumors
were incidentally identified during routine radiological
examination or radiological examination done for detection
of non-pancreatic lesions (Table 1). Approximately, twothirds were located in body and tail of pancreas. Surgical
resection was performed in 19 of 23 cases (82.6%). Distal
pancreatectomy with splenectomy was the commonest type
of surgical resection performed (Table 1). Tumor size
ranged from 2 to 16 cm in maximum dimension with
median and mean size of 5.5 and 6.4 cm ± 4.6 SD, respectively. According to the preoperative radiological films,
majority of these lesions presented as well-defined,
hypodense, cystic masses, mainly involving the body and
tail of the pancreas. In two cases, the lesions showed predominantly solid appearance. Cystic locules of variable
sizes, internal septations, calcifications, and peripancreatic
fat stranding were also observed in few cases (Figure 1(a)).
However, convincing radiological evidence of infiltration
into retroperitoneal fat was seen in only a single case.
Grossly, the lesions in our study were well circumscribed
with smooth or bosselated outer surfaces and cystic spaces
of variable sizes filled with clear or straw colored serous
fluid on cut surface. In few cases, cut surfaces showed solid
areas without grossly visible lumina. A gray white, fibrotic,
variably calcified central scar was seen in 10 cases (43.4%).
The cystic spaces ranged from 1 mm to 3 cm in diameter,
but the majority was smaller than 1 cm (Figure 1(b)). Of 23
cases, 2 (8.6%) were unilocular (Figure 2). Macroscopic
extension into retroperitoneal fat was seen in a single case
which had radiological evidence of retroperitoneal fat
involvement.
Microscopically, cystic spaces in all cases were lined
by a single layer of flattened to cuboidal epithelial cells
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with moderate amount of clear to faintly eosinophilic
cytoplasm. One case showed ciliated cuboidal epithelium
while another showed decapitation secretions. Epithelial

Table 1. Summary of clinical and histological features of serous
cystadenoma of pancreas patients (n = 23).
Tumor location
Body and tail of pancreas
Body of pancreas only
Tail of pancreas only
Head of pancreas
Uncinate process
Site not mentioned

Frequency, n (%)
6 (26.1)
2 (8.6)
5 (21.7)
6 (26.1)
1 (4.3)
3 (13.0)

Surgical procedure and type of biopsy

Frequency

Surgical resection
Distal pancreatectomy
Whipple’s procedure
Enucleation
Wedge/incisional biopsy
Block received for second opinion
Splenectomy

18 (81.8)
13 (59)
4 (17.4)
1 (4.3)
4 (17.4)
1 (4.3)
11 (50)

Histological features

Frequency

Micropapillae formation
Calcification
Hemorrhage
Lymphocytic infiltration
Peripancreatic fat extension
Entrapment of native pancreatic tissue
List of other non-pancreatic lesions (5 cases)
Ovarian thecoma
Gastric gastrointestinal stromal tumor (GIST)
Renal oncocytoma and uterine fibroid
Hepatocellular carcinoma/liver cirrhosis
Tuberculous lymphadenitis

8 (34.7)
7 (30.4)
4 (17.4)
4 (17.4)
4 (17.4)
8 (34.7)

cell nuclei were round, uniform, and centrally placed
(Figure 3(a) and (b)). Significant nuclear atypia or mitotic
activity was not seen in any of the cases. Cytoplasmic glycogen granules were highlighted on periodic acid Schiff
(PAS) stain and were washed out with diastase reaction
(Figure 3, inset). In few cases, micropapillae formation
was seen focally (Figures 3(c) and (d)). Intraluminal
eosinophilic secretions were seen in some cases (Figure
4(a)). Since H&E staining and PAS with diastase stains
were sufficient for establishing the diagnosis, immunohistochemical (IHC) stains were not performed. Central
stellate scar, when present, was composed histologically of acellular fibrous tissue with variable degree of
hyalinization and edematous change. Scattered foci of
dystrophic calcification, hemorrhage, and collections
of hemosiderin macrophages were also identified
(Figure 4(b) and (c)). In addition to the case with radiological and macroscopic evidence of retroperitoneal
fat involvement, focal extension into peripancreatic fat
and entrapment of native pancreatic tissue was seen
microscopically in four cases (17.4%) (Figure 4(d) and
Table 1).
Follow-up was available in all 23 cases. Follow-up duration ranged from 4 to 183 months with mean follow-up of
77.8 months ± 62.2 SD and median of 58 months. None of
the patients received adjuvant chemotherapy or radiotherapy. Only one patient (with tumor extension into retroperitoneal fat) developed local recurrence 4 years after initial
surgery. None of the patients developed metastasis or died
of disease. One patient died of liver disease (unrelated to
pancreatic tumor) 1 year after the diagnosis of SC.
Compared to 23 cases of SC, 11 cases of pancreatic mucinous cystic neoplasms (MCNs) and 2 cases of intraductal
papillary mucinous neoplasm (IPMN) were diagnosed during the study period (January 2001–June 2018). During the
same period, 115 cases of invasive pancreatic adenocarcinoma and 177 cases of ampullary adenocarcinoma were
diagnosed and managed.

Figure 1. (a) CT scan abdomen showing a well-defined, solid, hypodense mass lesion in pancreatic body with central popcorn-like
amorphous calcification. (b) Gross appearance of serous cystadenoma. Central fibrotic scar is evident along with multiple small-sized
cystic spaces. Normal pancreatic tissue is present at the periphery.
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Discussion
A variety of cystic lesions can occur in the pancreas and
range from benign entities such as pseudocysts and SCs to
tumors with potential for aggressive behavior such as
MCNs and IPMNs. Moreover, solid pancreatic tumors such

Figure 2. Low-power view of unilocular variant exhibiting a
single large cystic locule lined by single layer of cells. Inset: PAS
special stain highlighting intracytoplasmic glycogen granules.
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as solid pseudopapillary tumor and invasive ductal adenocarcinoma can acquire a cystic appearance due to degenerative or necrotic changes.17 In 1978, SCs of pancreas were
separated from pancreatic mucinous cystic neoplasms.18,19
Based on the IHC and ultrastructural findings, SCs are
believed to be derived from intercalated duct cell or centroacinar cell lineage.20,21
SCs occur over a wide age range. Various published
studies, have reported age ranges from 24 to 93 years with
mean age at presentation in sixth and seventh decades.1,4
We also observed similar age distribution in our series, as
majority (65.2%) of our patients were in their fifth to seventh decades when diagnosed. Females are three times
more commonly affected than males.5 In our study also,
marked female preponderance was noted. These tumors
can present with abdominal pain, palpable mass, vomiting,
nausea, weight loss, and so on. Jaundice is uncommon but
can be seen in tumors involving the head of pancreas secondary to occlusion of common bile duct.1,5,20 However,
almost half are detected incidentally during radiological
examination performed for detection of possible nonpancreatic lesions.14 It is possible nowadays to accurately
diagnose SCs by performing MRI or endoscopic ultrasound, and so on, without need of biopsy other invasive techniques.16 In our study, over 55% patients were
asymptomatic and were diagnosed incidentally. Abdominal

Figure 3. Microscopic features of serous cystadenoma: (a) low-power view showing small cystic space lined by single layer of
cuboidal cells, (b) high-power view showing cuboidal cells with moderate amount of lightly eosinophilc granular cytoplasm and
centrally placed, rounded, uniform nuclei, (c) low-power view of micropapillae, and (d) high-power view of micropapillae.
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Figure 4. Microscopic features of serous cystadenoma: (a) eosinophilic secretions in cyst lumina, (b) central scar exhibiting
hyalinization and calcification, (c) hemorrhage and hemosiderin-laden macrophages, and (d) normal pancreatic tissue entrapped
within cyst walls/septae.

pain, jaundice, abdominal mass, nausea, and vomiting were
the main symptoms noticed in our patients. Only two
patients in our series (with tumors in pancreatic head) presented with jaundice. Tumor sizes in published studies have
ranged from 1 to 25 cm with mean size of 6 cm.1 In our
series also, wide range was seen in tumor size from as small
as 2 cm to as large as 16 cm. Grossly, the usual microcystic
forms appear as well-circumscribed lesions with smooth
rounded or bosselated outer surfaces. Cut surfaces show
numerous microcysts with irregular contours and diameters
ranging from less than a millimeter to more than a centimeter.1 A fibrous stellate scar with or without calcification is
seen in up to 30% cases and provides a useful diagnostic
clue.3 In our study, central scar was seen in 43.4% tumors.
One of the recent studies divided the microcystic form of
SC into “microcystic, classical type” which have very few
larger cystic locules (measuring in centimeters) and “microcystic with prominent macrocystic component” which have
a prominent component of large cystic locules, although the
usual microcystic pattern still predominates.4 The lesscommon macrocystic variant was described in older studies
as “serous oligocystic ill-demarcated adenoma of pancreas.”
Macrocystic variants are poorly demarcated and contain
larger cystic locules, which measure more than a centimeter
in diameter each and are typically less than 10 in number.
In some cases, the lesion comprises of a single locule

only.1,4,11,12 Such unilocular lesions occur more frequently
in pancreatic head of elderly males.1,2 However, a recent
study on a larger cohort of cases reported that this variant
occurs in a younger age group as compared to microcystic
form (50 vs 61 years) but shows similar female predominance and predilection for body and tail region.4 In our
cohort, two patients had unilocular tumors. One of these
patients was a 23-year-old female with tumor in pancreatic
tail. The other patient was a 68-year-old male with tumor in
the head of the pancreas. Solid variant of SC is rare, and so
far, only 20 sporadic cases have been reported. It comprised
only 2% of cases in a large study on SCs. It has no gender
or site (head vs body and tail) predilection and usually
occurs in the sixth and seventh decades of life. In most
cases, tumor size is between 2 and 4 cm. Grossly, these are
well-circumscribed, grayish brown nodules with shiny cut
surfaces, and do not have a central scar. Microscopically,
the solid variant of SC is composed of closely packed,
small, uniform tubules, and acini with little or no lumina
formation.4,22 Turcotte et al.23 reported 10 (18.2%) cases of
solid microcystic SC in a cohort of 55 VHL patients with
SC. A few cases in our study grossly showed solid areas,
but this appearance was not predominant on the cut surface
of the lesion and these tumors did not meet the criteria for
“solid variant” of SC. Fine needle aspiration of these lesions
does not provide a good yield of diagnostic material due to
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paucicellular nature of these lesions and cohesiveness of
the epithelial cells.4,24
Pancreatic lesions are seen in 35%–70% cases of VHL
disease.25 Majority of these lesions are asymptomatic simple cysts, which usually do not require excision. According
to World Health Organization (WHO) classification of pancreatic serous neoplasms, “VHL-associated serous cystic
neoplasms” are a group of lesions, which can appear in
microcystic, macrocystic, and solid forms. In VHL disease
patients, they can diffusely involve pancreas or occur as
multiple lesions. Microscopically, they have simple cuboidal epithelial lining of glycogen-rich, clear cells.1,23 Apart
from their association with pancreatic neuroendocrine
tumors (PanNET) in VHL disease, they are also seen in
patients with various other neoplastic and non-neoplastic
pancreatic and non-pancreatic lesions.1,3,4 Most frequent
molecular abnormalities observed in sporadic SC cases
include allelic losses on 10q (50%) and 3p (40%). In addition, somatic inactivating mutations of VHL gene are
observed in 22% of sporadic SCs.26 We encountered a number of non-pancreatic lesions in our group of patients (Table
1). Molecular testing for VHL disease was not performed in
any of our cases, since it was not available in any laboratory
in the country. Association of these neoplastic lesions with
SCs has not been explained until now. However, in our
opinion, frequent simultaneous occurrence of these lesions
raises a possibility of their common association with some
other syndrome.
In the majority of cases, the diagnosis is straightforward
due to peculiar cytomorphology. However, these tumors
may show heterogeneity in their histological features. We
observed heterogeneous features including micropapillae
formation, calcification, hemorrhage, lymphocytic infiltration, peripancreatic fat extension, and entrapment of native
fat in a number of our cases. In cases with denuded epithelial lining, benign vascular lesions such as lymphangioma
and hemangioma need to be considered in the differential
diagnosis. The presence of smaller tubules with intact epithelium at the periphery provides a diagnostic clue. The
presence of cytoplasmic glycogen granules and lack of
cytoplasmic mucin rules out other pancreatic mucinous
cystic neoplasms. Metastatic renal cell carcinoma (RCC) is
another important differential diagnosis in cases where the
tubules are smaller and closely packed. Clinical history and
PAX-8 expression in RCC help in distinction between the
two entities. PanNETs and clear-cell sugar tumors are other
close differentials, especially in solid variant of SC.
PanNETs occurring in patients with VHL disease exhibit
clear-cell morphology, but expression for neuroendocrine
markers helps in differentiation from pancreatic SCs.1 SCs
demonstrate positive expression for epithelial membrane
antigen (EMA), cytokeratins, α-inhibin, MUC6 and
MUC1 stains, and negative expression for neuroendocrine markers.20 All cases in our study showed typical
cuboidal to flattened epithelial cells with round, uniform
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nuclei, and clear, glycogen-rich cytoplasm. The epithelial
lining can exhibit focal pseudopapillae formation. The central scar may show hyalinization, edema, hemorrhage,
chronic inflammation, and calcification in variable proportions. We have reported the frequency and percentages of
these features in our cases in detail (Table 1). Few studies
have described these morphological features in such detail.
Despite gross demarcation and circumscription, 4 (17.4%)
tumors in our study showed focal extension into the peripancreatic fat on microscopic examination. However, none
of these tumors had recurred at the time of last follow-up.
The only case in our study which showed recurrence had
radiological and macroscopic evidence of retroperitoneal
fat extension. We feel that surgical excision with clear margins is sufficient to prevent recurrence.
Complete surgical resection is curative in all cases of
pancreatic SC but is recommended only in a small minority
of cases in which preoperative diagnosis remained uncertain in spite of extensive radiological workup or when
tumors were large in size or were causing significant tumorrelated symptoms. It is also recommended in the exceptional cases in which a concern of malignancy exists.16
However, in poor developing countries such as Pakistan
and Afghanistan, radiological facilities for accurate noninvasive diagnosis of pancreatic neoplasms are suboptimal
in most areas, and the importance of not missing and adequately treating mucinous pancreatic neoplasms, which
have aggressive malignant potential, means that at least for
the near future, surgical resection may continue to be performed for the majority of pancreatic cystic neoplasms
regardless of whether they are serous or mucinous. In view
of the postoperative morbidity and mortality associated
with pancreatic surgeries, asymptomatic, and uncomplicated small tumors are managed conservatively. Surgical
excision may be recommended for symptomatic and larger
(>4 cm) tumors.14,16 Of the 23 patients in our study, 16 had
tumors larger than 4 cm in diameter. In the remaining three
cases in which resection was performed, the diameter was
less than 4 cm. Since surgery in these three cases was performed outside our institution, exact indication for surgery
is not known. Although majority of pancreatic SCs are
benign, few are locally aggressive and sometimes extend
into the peripancreatic tissues. These locally aggressive
SCs have a greater potential for recurrence and therefore,
warrant close follow-up.5 Most of our patients underwent
surgical resection, and the exact type of surgical procedure
was chosen on the basis of exact location of these tumors in
the pancreas. Four patients only had incisional biopsy and
the disease remained stable (until the time of last followup). One patient in our series with a pancreatic head tumor
and radiological and gross extension into the retroperitoneal fat developed recurrence 4 years after initial resection
of tumor.
Serous cystic neoplasms are slow-growing tumors with
excellent prognosis. The incidence of malignancy was
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reported as 3% in a large study.27 According to the WHO
classification, distant metastasis is the only criterion for
malignancy.1 A recent large study by Reid et al.4 showed
that cases of SC of pancreas with hepatic involvement actually represented synchronous and metachronous multifocal
primary hepatic and pancreatic SCs rather than hepatic
extension/metastasis from the pancreatic tumor. All patients
in our study had a very good clinical course with not a single instance of metastasis or tumor-related death even several years after surgical removal.
It is absolutely essential to make an accurate diagnosis.
Confusion with pancreatic ductal adenocarcinomas may be
catastrophic for the patient. Ductal adenocarcinomas of the
pancreas are highly aggressive tumors and the vast majority
have already spread beyond the pancreas at the time of
diagnosis. They are fatal in almost all cases with mean survival times ranging from 3 to 5 months in untreated patients
and 10–20 months after surgical resection. The tumors are
surgically resectable at the time of diagnosis in only 10%–
20% cases. Current newly developed neoadjuvant treatments are employed in unresectable cases. However, even
adjuvant chemotherapy with gemcitabine or 5-fluorouracil
prolongs survival times very slightly. On the other hand,
SCs have excellent prognosis and can often be managed
conservatively and as discussed above requires surgical
resection in only selected cases. Neoadjuvant treatments
are definitely not required, and in case of incorrect diagnosis, patients may be subjected to unnecessary, even
harmful surgery (potentially significant postoperative
morbidity and mortality especially in elder patients) and
totally unnecessary getting harmful neoadjuvant chemotherapy. The importance of correct diagnosis and the need
to distinguish SC from pancreatic adenocarcinomas cannot be overemphasized.1,28–33

Conclusion
SCs of pancreas are benign pancreatic neoplasms with distinct clinical, radiological, and histological features in the
majority of cases. Distinction from more aggressive pancreatic cystic lesions is important and can be done by radiological and, in some cases, by histologic evaluation of
adequate biopsy material. Clinical course is excellent.
Recurrence is uncommon and tumor-related deaths are
almost nil. Large majority of cases require only conservative initial management, and surgical resection is required
only in a minority of cases. However, in poor developing
countries such as ours, surgical resection may still be performed in the majority of cases owing to lack of optimum
radiological services hindering non-invasive diagnosis of
these tumors and the importance of ensuring that mucinous
pancreatic neoplasms owing to their aggressive potential
are not missed and are treated adequately.
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